News Lilly’s sarcoma drug Lartruvo recommended via Cancer Drugs F... Lilly's drug will be re-appraised in 2020
News AbbVie looks beyond Humira as RA pill meets phase 3 targets Upadacitinib hopes drug will reduce reliance on Humira.
News Teva plans migraine drug filing later this year Blockbuster hopeful could launch next year if approved.
News Merck tries again in Alzheimer's with Teijin's tau antibody Target is implicated in a number of nervous system diseases.
News Data keeps Lilly in race for new migraine treatment Company still in race to develop CGRP inhibitor for migraine.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.